Once-daily mometasone furoate dry powder inhaler in the treatment of patients with persistent asthma

Nayak, Anjuli; Banov, Charles H.; Corren, Jonathan; Feinstein, Barry K.; Floreani, Anthony A.; Friedman, Bruce; Goldsobel, Alan B.; Gottschlich, Gregory; Hannaway, Paul J.; Lampl, Kathy; Lapidus, Robert; Lawrence, Michael C.; Lumry, William R.; Munk, Zev M.; Pearlman, David S.; Scardella, Anthony; Schenkel, Eric; Segal, Allen T.; Segall, Nathan; Silverman, Bernard A.; Shneyer, Lucy; Nolop, K. B.; Je, Harrison

doi:10.1016/s1081-1206(10)62275-2

Cited by 77 publications

(50 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several pivotal studies have been carried out on seasonal allergic rhinitis comparing montelukast and placebo. In some studies, the combination of montelukast-loratadine was also used (1521,1523,(1582)(1583)(1584). It was consistently found that montelukast was more effective than placebo for all nasal and ocular symptoms and that there was no significant difference between montelukast and loratadine, even for nasal obstruction.…”

Section: Intranasal Glucocorticosteroidsmentioning

confidence: 99%

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

Bousquet¹,

Khaltaev²,

Cruz³

et al. 2008

Allergy

3,859

1,761

View full text Add to dashboard Cite

Section: Intranasal Glucocorticosteroidsmentioning

confidence: 99%

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

Bousquet¹,

Khaltaev²,

Cruz³

et al. 2008

Allergy

3,859

1,761

View full text Add to dashboard Cite

“…There is no information on the role of CIC-AM esterification on the retention of CIC-AM in the airways, and once daily efficacy of CIC (Chapman et al, 2005;Pearlman et al, 2005) may be due to other CIC and CIC-AM features, such as high lipophilicity. For example, MF is reported to be effective at once daily inhalation (Nayak et al, 2000;Karpel et al, 2005), although it does not form esters.…”

mentioning

confidence: 99%

Differences in Endogenous Esterification and Retention in the Rat Trachea between Budesonide and Ciclesonide Active Metabolite

Lexmuller

Gullstrand²,

Axelsson³

et al. 2007

Drug Metab Dispos

View full text Add to dashboard Cite

ABSTRACT:The airway retention of inhaled glucocorticosteroids (GCs) depends largely on their lipophilicity. Inhaled budesonide (BUD) becomes highly lipophilic reversibly by the formation of esters acting as a reservoir of active BUD. Ciclesonide (CIC) was also reported to form esters after hydrolysis to active metabolite (CIC-AM). We have investigated lipophilicity and airway retention of BUD, CIC/ CIC-AM, fluticasone propionate (FP), and mometasone furoate (MF), and compared esterification of BUD and CIC-AM and its contribution to GC airway retention. Rat tracheas were preincubated with the esterification inhibitor cyclandelate or vehicle. A 3 H-GC (ϳ10 ؊7 M: BUD, CIC, CIC-AM, FP, MF) was added for 20 min.After incubation, one half of the trachea was used for analysis of GC uptake and the other to analyze GC release during 3 h in drug-free medium. GC species in trachea halves were analyzed by radiochromatography. At 20 min, the uptake of BUD was similar to that of CIC/CIC-AM; however, the BUD-ester pool was 9-fold greater (p < 0.01). BUD overall retention in trachea at 3 h was greater than that of other GCs (p < 0.01), and the BUD-ester pool was 3-fold greater than the CIC-AM-ester pool (p < 0.01). Cyclandelate decreased the initial BUD-and CIC-AM-ester pools (p < 0.01), and reduced the overall retention of BUD at 3 h (p < 0.01) but not of CIC-AM. Thus, BUD becomes esterified in the airways more promptly and to a greater extent than CIC-AM, and BUD esterification prolongs BUD airway retention. In contrast, airway retention of CIC-AM and CIC seems to be determined mainly by their lipophilicity, similar to FP and MF, which are not esterified.

show abstract

“…At screening, median plasma cortisol levels were 13.3 mg . dL [12,13] which demonstrated MF DPI to be effective and well tolerated. In the present study, MF DPI was directly compared to a clinically effective and widely used inhaled glucocorticoid, BUD Turbuhaler1.…”

Section: Evaluation Of Safetymentioning

confidence: 96%

“…min -1 [11]. The MF DPI was shown to be very effective in the treatment of mild to moderate persistent asthma [12,13].…”

mentioning

confidence: 99%

Comparison of the efficacy and safety of mometasone furoate dry powder inhaler to budesonide Turbuhaler

Bousquet¹,

D’Urzo²,

Hébert³

et al. 2000

Eur Respir J

View full text Add to dashboard Cite

Significant superiority (p<0.05) was also seen in scores for several secondary efficacy variables when MF DPI was compared with BUD Turbuhaler1 treatment. MF DPI 200 mg b.i.d was comparable to MF DPI 400 mg b.i.d in therapeutic benefit. The incidence of oral candidiasis was no more than 3% in any group. All treatments were well tolerated.A total daily dose of 400 mg of mometasone furoate administered by dry powder inhaler provides a well-tolerated treatment for patients with moderate persistent asthma and results in a significantly greater improvement, when compared to a daily dose of 800 mg BUD Turbuhaler1 in the parameters measured in this study. Eur Respir J 2000; 16: 808±816.

show abstract

Once-daily mometasone furoate dry powder inhaler in the treatment of patients with persistent asthma

Cited by 77 publications

References 26 publications

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

Differences in Endogenous Esterification and Retention in the Rat Trachea between Budesonide and Ciclesonide Active Metabolite

Comparison of the efficacy and safety of mometasone furoate dry powder inhaler to budesonide Turbuhaler

Contact Info

Product

Resources

About